(PDF) Assessment of the Long-Term Safety of Mepolizumab and

Assessment of the Long-Term Safety of Mepolizumab and Durability of Clinical Response in Patients With Severe Eosinophilic Asthma

Journal of Allergy and Clinical Immunology - United States

doi 10.1016/j.jaci.2018.09.033

Full Text

Abstract

Available in full text

Categories

Date

May 1, 2019

Authors

Peter G. Gibson

Frank C. Albers

Eric S. Bradford

Robert G. Price

Steven W. Yancey

Publisher

Elsevier BV

Related search

Long-Term Efficacy and Safety of Mepolizumab in Patients With Severe Eosinophilic Asthma: A Multi-Center, Open-Label, Phase IIIb Study

Clinical Therapeutics

English

Real-World Safety of Treatment With Mepolizumab and Reslizumab in Patients With Severe Eosinophilic Asthma

Journal of Allergy and Clinical Immunology

English

Patients With Severe Eosinophilic Asthma Treated With Mepolizumab: Results From Our Clinical Practice

Journal of Allergy and Clinical Immunology

English

Prs55 - Cost-Effectiveness of Mepolizumab in Severe Eosinophilic Asthma Patients in France

Value in Health

Occupational Health

English

Efficacy and Safety of Treatment With Biologicals (Benralizumab, Dupilumab, Mepolizumab, Omalizumab and Reslizumab) for Severe Eosinophilic Asthma

Allergy: European Journal of Allergy and Clinical Immunology

English

Mepolizumab for Severe Refractory Eosinophilic Asthma: Evidence to Date and Clinical Potential

Therapeutic Advances in Chronic Disease

English

Bronchial Thermoplasty: Long-Term Safety and Effectiveness in Patients With Severe Persistent Asthma

Journal of Allergy and Clinical Immunology

English

Prospective Open-Label Study of 48-Week Subcutaneous Administration of Mepolizumab in Japanese Patients With Severe Eosinophilic Asthma

Journal of Allergy and Clinical Immunology

English

Favorable Clinical Efficacy of Mepolizumab on the Upper and Lower Airways in Severe Eosinophilic Asthma: A 48-Week Pilot Study

European Annals of Allergy and Clinical Immunology

English